[go: up one dir, main page]

EP1812064A4 - USE OF ENDOTHELIAL VASCULAR GROWTH FACTOR RECEPTOR CELLS IN THE TREATMENT AND MONITORING OF CANCER AND IN THE SCREENING OF CHEMOTHERAPEUTIC AGENTS - Google Patents

USE OF ENDOTHELIAL VASCULAR GROWTH FACTOR RECEPTOR CELLS IN THE TREATMENT AND MONITORING OF CANCER AND IN THE SCREENING OF CHEMOTHERAPEUTIC AGENTS

Info

Publication number
EP1812064A4
EP1812064A4 EP05856987A EP05856987A EP1812064A4 EP 1812064 A4 EP1812064 A4 EP 1812064A4 EP 05856987 A EP05856987 A EP 05856987A EP 05856987 A EP05856987 A EP 05856987A EP 1812064 A4 EP1812064 A4 EP 1812064A4
Authority
EP
European Patent Office
Prior art keywords
cancer
screening
monitoring
treatment
growth factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05856987A
Other languages
German (de)
French (fr)
Other versions
EP1812064A2 (en
Inventor
David Lyden
Rosandra N Kaplan
Rebecca D Riba
Shahin Rafii
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cornell Research Foundation Inc
Original Assignee
Cornell Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cornell Research Foundation Inc filed Critical Cornell Research Foundation Inc
Publication of EP1812064A2 publication Critical patent/EP1812064A2/en
Publication of EP1812064A4 publication Critical patent/EP1812064A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP05856987A 2004-11-19 2005-11-21 USE OF ENDOTHELIAL VASCULAR GROWTH FACTOR RECEPTOR CELLS IN THE TREATMENT AND MONITORING OF CANCER AND IN THE SCREENING OF CHEMOTHERAPEUTIC AGENTS Withdrawn EP1812064A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62966204P 2004-11-19 2004-11-19
US72377005P 2005-10-05 2005-10-05
PCT/US2005/042125 WO2006083355A2 (en) 2004-11-19 2005-11-21 Use of vascular endothelial growth factor receptor 1+ cells in treating and monitoring cancer and in screening for chemotherapeutics

Publications (2)

Publication Number Publication Date
EP1812064A2 EP1812064A2 (en) 2007-08-01
EP1812064A4 true EP1812064A4 (en) 2009-07-08

Family

ID=36794839

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05856987A Withdrawn EP1812064A4 (en) 2004-11-19 2005-11-21 USE OF ENDOTHELIAL VASCULAR GROWTH FACTOR RECEPTOR CELLS IN THE TREATMENT AND MONITORING OF CANCER AND IN THE SCREENING OF CHEMOTHERAPEUTIC AGENTS

Country Status (3)

Country Link
US (2) US7598043B2 (en)
EP (1) EP1812064A4 (en)
WO (1) WO2006083355A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007305443B2 (en) * 2006-09-29 2012-08-23 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
US20110110940A1 (en) * 2008-04-15 2011-05-12 Oxigene, Inc. Methods for Enhancing the Efficacy of Vascular Disrupting Agents
EP3072526B1 (en) 2009-10-16 2018-09-26 Oncomed Pharmaceuticals, Inc. Therapeutic combination and use of dll4 antagonist antibodies and anti-hypertensive agents
DE102009060317B4 (en) * 2009-12-23 2013-04-04 Siemens Aktiengesellschaft A contrast agent for use in an imaging method for diagnosing a metastatic tumor disease and a method for imaging a metastatic tumor tissue
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
EP2678424B1 (en) * 2011-02-24 2019-07-03 Cornell University Bone marrow-derived hematopoietic progenitor cells and endothelial progenitor cells as prognostic indicators for cancer
US9816998B2 (en) 2011-04-01 2017-11-14 Cornell University Circulating exosomes as diagnostic/prognostic indicators and therapeutic targets of melanoma and other cancers
EP2758073B1 (en) 2011-09-23 2018-10-31 OncoMed Pharmaceuticals, Inc. Vegf/dll4 binding agents and uses thereof
EP2914961A4 (en) 2012-10-31 2016-04-20 Oncomed Pharm Inc METHODS AND MONITORING A TREATMENT BY AN ANTAGONIST OF DLL4
CN107530419B (en) 2014-10-31 2021-05-18 昂考梅德药品有限公司 Combination therapy to treat disease
JP6967003B2 (en) 2015-09-23 2021-11-17 メレオ バイオファーマ ５ インコーポレイテッド Methods and compositions for the treatment of cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003006059A1 (en) * 2001-07-13 2003-01-23 Imclone Systems Incorporated Vegfr-1 antibodies to treat breast cancer

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
IL89489A0 (en) 1988-03-09 1989-09-10 Hybritech Inc Chimeric antibodies directed against human carcinoembryonic antigen
JPH02503867A (en) 1988-04-15 1990-11-15 プロテイン　デザイン　ラブズ　インコーポレーテッド IL-2 receptor-specific chimeric antibody
CA1341411C (en) 1988-04-16 2002-12-17 Lutz Riechmann Method for producing fv fragments in eukaryotic cells
AU662311B2 (en) 1991-02-05 1995-08-31 Novartis Ag Recombinant antibodies specific for a growth factor receptor
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
WO1993021319A1 (en) 1992-04-08 1993-10-28 Cetus Oncology Corporation HUMANIZED C-erbB-2 SPECIFIC ANTIBODIES
US20030108545A1 (en) 1994-02-10 2003-06-12 Patricia Rockwell Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
US6811779B2 (en) * 1994-02-10 2004-11-02 Imclone Systems Incorporated Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy
US6448077B1 (en) * 1994-02-10 2002-09-10 Imclone Systems, Inc. Chimeric and humanized monoclonal antibodies specific to VEGF receptors
JPH11507535A (en) 1995-06-07 1999-07-06 イムクローン システムズ インコーポレイテッド Antibodies and antibody fragments that suppress tumor growth
AU731927B2 (en) * 1996-11-21 2001-04-05 Kyowa Hakko Kirin Co., Ltd. Anti-human VEGF receptor F1t-1 monoclonal antibody
DE60118186T2 (en) * 2000-05-12 2006-12-28 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. USE OF PLAZENTA GROWTH FACTOR INHIBITORS FOR THE TREATMENT OF A PATHOLOGICAL ANGIOGENESIS, PATHOLOGICAL ARTERIOGENESIS, INFLAMMATION, TUMOR FORMATION AND / OR VASCULARITY OF LIQUIDITY (ÖDEM)
CA2494870A1 (en) * 2001-08-06 2003-03-06 The Regents Of The University Of California Methods for inhibiting angiogenesis
ES2299590T3 (en) 2001-08-10 2008-06-01 Imclone Systems, Inc. MEDICAL USE OF MOTHER CELLS THAT EXPRESS VEGFR-1.NG VEGFR-1.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003006059A1 (en) * 2001-07-13 2003-01-23 Imclone Systems Incorporated Vegfr-1 antibodies to treat breast cancer

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
"Adult acute myeloid leukemia treatment", 9 October 2009 (2009-10-09), Retrieved from the Internet <URL:text extract taken from the website of the US National Cancer Institute> [retrieved on 20101018] *
DE PALMA MICHELE ET AL: "Targeting exogenous genes to tumor angiogenesis by transplantation of genetically modified hematopoietic stem cells.", NATURE MEDICINE, vol. 9, no. 6, June 2003 (2003-06-01), pages 789 - 795, XP002527465, ISSN: 1078-8956 *
DIAS S ET AL: "NEUTRALIZING MOAB TO VERGF RECEPTORS INHIBIT PROFIFERATION AND MIGRATION OF A SUDSET OF HUMAN LEUKEMIAS THROUGH INTERACTION WITH VERGFR-2(KDR) AND VEGFR-1(FLT-1)", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 94, no. 10,SUPPL.01PT01, 15 November 1999 (1999-11-15), pages 620A, XP001021704, ISSN: 0006-4971 *
KAPLAN J G ET AL: "Leptomeningeal metastases: comparison of clinical features and laboratory data of solid tumors, lymphomas and leukemias.", JOURNAL OF NEURO-ONCOLOGY DEC 1990 LNKD- PUBMED:2086737, vol. 9, no. 3, December 1990 (1990-12-01), pages 225 - 229, XP009140125, ISSN: 0167-594X *
KAPLAN R N ET AL: "VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche", NATURE 20051208 NATURE PUBLISHING GROUP GB, vol. 438, no. 7069, 8 December 2005 (2005-12-08), pages 820 - 827, XP002527463 *
WU Y ET AL: "MONOCLONAL ANTIBODY AGAINST VEGFR1 INHIBITS FLT1-POSITIVE BREAST TUMOR GROWTH BY A DUAL MECHANISM INVOLVING ANTI-ENDOTHELIAL AND ANTI-TUMOR CELL GROWTH ACTIVITIES", PROCEEDINGS OF THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, NEW YORK, NY, vol. 43, 1 March 2002 (2002-03-01), pages 527, XP008023695, ISSN: 0197-016X *
YANG ANTHONY D ET AL: "Vascular endothelial growth factor receptor-1 activation mediates epithelial to mesenchymal transition in human pancreatic carcinoma cells", CANCER RESEARCH, vol. 66, no. 1, January 2006 (2006-01-01), pages 46 - 51, XP002527464, ISSN: 0008-5472 *

Also Published As

Publication number Publication date
US8465738B2 (en) 2013-06-18
US20060134080A1 (en) 2006-06-22
EP1812064A2 (en) 2007-08-01
WO2006083355A2 (en) 2006-08-10
WO2006083355A3 (en) 2007-01-11
US7598043B2 (en) 2009-10-06
US20100150932A1 (en) 2010-06-17

Similar Documents

Publication Publication Date Title
EP1812064A4 (en) USE OF ENDOTHELIAL VASCULAR GROWTH FACTOR RECEPTOR CELLS IN THE TREATMENT AND MONITORING OF CANCER AND IN THE SCREENING OF CHEMOTHERAPEUTIC AGENTS
EP1487857A4 (en) BLOOD AND LYMPHATIC ENDOTHELIAL CELL GENES
FR08C0051I2 (en) SUBSTITUTE OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION
ATE374204T1 (en) THIENOPYRIMIDINEDIONE AND THEIR USE IN THE TREATMENT OF AUTOIMMUNE DISEASES
DE602005004452D1 (en) Urine collection device and collected urine processing system including urine collection device
ATE297380T1 (en) MCH ANTAGONISTS AND THEIR USE IN THE TREATMENT OF OBESITY
ATE447552T1 (en) MCH ANTAGONISTS AND THEIR USE IN THE TREATMENT OF OBESITY
EP1583581A4 (en) METHODS AND DEVICES FOR CARRYING OUT CARE IN THE FIELD OF CARDIAC VALVES
DE60112791D1 (en) Piperidin MCH Antagonists and their use in the treatment of obesity
EP2451284A4 (en) GOLD-BASED NANOCRYSTALS USED IN MEDICAL TREATMENT AND ELECTROCHEMICAL METHODS OF MAKING SAME
EP1720584A4 (en) VESSEL OR SACK WALL TREATMENT AND HEART SUPPORT DEVICE
EP1841466A4 (en) AGENTS FOR MONITORING THE THERAPEUTIC EFFICIENCY AND IMAGING OF THE DEEP TISSUES
EP1913112A4 (en) SUPPORTING AGENT AND METHODS OF USE
EP1495130A4 (en) USE OF BIOMOLECULAR TARGETS IN THE TREATMENT AND VISUALIZATION OF BRAIN TUMORS
EP1689435A4 (en) ANTI-THYMOCYTE ANTISERUM AND USE THEREOF TO DECLINE APOPTOSIS FROM B CELLS
DE602004013101D1 (en) Automatic device for collecting and collecting urine
EP2515795A4 (en) REVERSIBLE VASCULAR FILTER DEVICES AND METHODS OF USING THE SAME
EP2185202A4 (en) USE OF INTERLEUKIN-22 IN THE TREATMENT OF HEPATIC STEATOSIS
EP1850665A4 (en) AGENTS FOR COMBATTING THE CARPOCAPSE OF APPLE AND PEAR IN ORCHARDS
EP1803160A4 (en) IMPROVING POSTLIBERATIVE CAPACITY IN MICRO-FACTORY DEVICES AND METHOD OF EXECUTING THE SAME
MA28737B1 (en) 2- (PYRIDIN-2-YL) -PYRIMIDINES AND THEIR USE IN THE CONTROL OF FUNGUS PARASITES
DZ3209A1 (en) Selective iGLuR5 receptor antagonists used in the treatment of migraine.
DE60325967D1 (en) STIMULATION OF HEMATOPOIESE IN EX VIVO-ACTIVATED IMMUNOCELLS
EP1957095A4 (en) MODIFIED ANNEXIN PROTEINS AND METHODS OF USE THEREOF IN ORGAN TRANSPLANTATION
EP1505871A4 (en) RNA CONSERVATION AND MORPHOLOGY IN CELLS AND TISSUE

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070518

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK YU

RIN1 Information on inventor provided before grant (corrected)

Inventor name: RIBA, REBECCA, D.

Inventor name: RAFII, SHAHIN

Inventor name: LYDEN, DAVID

Inventor name: KAPLAN, ROSANDRA, N.

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: CORNELL RESEARCH FOUNDATION, INC.

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20090608

17Q First examination report despatched

Effective date: 20101102

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20161206

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20170419